CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression

Launched by AFFILIATED HOSPITAL OF NANTONG UNIVERSITY · Nov 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain genetic factors in patients with depression affect the levels of a medication called agomelatine in their blood. Agomelatine is used to help improve mood and sleep. The researchers will look at specific genes (CYP1A2, ABCB1, and CYP2C9) that might influence how well the body processes this medication. By understanding these genetic differences, the goal is to create a personalized medication guide to help doctors prescribe agomelatine more effectively.

To be eligible for this trial, participants should be adults aged 18 to 75 who have been diagnosed with depression and also experience sleep problems. However, those with certain serious conditions, such as severe heart or liver issues, or other mental disorders, will not be able to join. Participants can expect to provide blood samples for testing and will help researchers learn more about how genetics can influence medication effectiveness. This trial is not yet recruiting, so there will be more details to come for interested individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of depression; Sleep disorder.
• Exclusion Criteria:
• • Mental disorder; Intelligence disorder; Dementia; Aphasia; Dysarthria; Consciousness disorder; Severe heart, kidney or liver dysfunction; Pregnant and lactating women; Malignant tumor.